Business Wire

Ennov Appoints Oxana Pickeral as Chief Executive Officer

9.9.2026 16:00:00 CEST | Business Wire | Press release

Share

Ennov (the “Company”), a global provider of a unified compliance platform that streamlines regulatory, clinical, quality, and pharmacovigilance operations for life sciences and healthcare companies, today announced the appointment of Dr. Oxana Pickeral as Chief Executive Officer. Founder and outgoing CEO, Olivier Pâris, will join Ennov’s Board of Directors and continue to support the company as a Strategic Advisor.

Dr. Pickeral has spent her career at the forefront of innovation in life sciences technology, from her early work on the Human Genome Project to growing Amazon Web Services’ Healthcare & Life Sciences partner business, enabling modern cloud solutions across the industry. She joins Ennov most recently from Honeywell, where she served as Global Software and Connected Life Sciences business leader, and previously as President and CEO of Sparta Systems, a Honeywell company. Across her leadership roles, she has successfully scaled global companies at the intersection of life sciences, healthcare, and technology innovation to drive outstanding products and outcomes for all stakeholders in the ecosystem.

“I am honored to join Ennov, a company known for its strong products, customer focus, and long-term commitment to healthcare and life sciences,” said Dr. Pickeral. “In our next chapter of growth, we will continue to innovate, scale our global operations, and work hand-in-hand with our customers through one of the most exciting phases of business change: navigating the impact of agentic AI, supply chain realignments, and the ever-increasing pace of R&D. I look forward to working closely with our team, Board, customers, and partners to deliver solutions that ultimately help improve the lives of patients and their families around the world.”

Since founding Ennov in 1999, Olivier Pâris has led its development into a global business serving ~650 customers and over 500,000 users worldwide. “We always built Ennov to lead on innovation and customer experience, with the goal of supporting and improving the processes and innovation of the global life sciences and healthcare industry,” said Olivier Pâris. “As we continue to pursue our global growth ambitions and stay true to our mission of innovating on behalf of our customers, I am thrilled to welcome Oxana as Ennov’s CEO and am pleased to have found a leader who embodies the traits that made Ennov so successful, while bringing a forward-looking vision that will ensure Ennov continues to deliver for its customers, partners, and employees.”

Under Pickeral’s leadership, Ennov will accelerate its ongoing efforts to embed AI across its unified platform, which is uniquely architected to enable agentic regulatory, quality, and clinical workflows tapping into its single data lake and highly configurable architecture. Further, the Company plans to establish a North American delivery and commercial hub to complement its existing footprint, while continuing to expand its international go-to-market capabilities in Europe and Asia. These priorities build on the recent investment in Ennov by Bregal Sagemount, a leading NYC-based growth-focused private equity firm, with participation from Ardian, a global private investment firm headquartered in France. Both firms bring extensive experience and resources in scaling global healthcare and life sciences technology companies with a focus on accelerating growth and innovation.

“Oxana brings unique leadership experience in scaling global technology companies in the life sciences space, while preserving and enhancing the innovation engine that made those companies indispensable to their customers,” said Gene Yoon, Managing Partner at Bregal Sagemount. “Over 25 years, Olivier and his team built Ennov into the clear innovation leader in technology for life sciences regulatory processes, and Oxana is the right leader to ensure that Ennov can continue to deliver on that track record, while expanding the Company’s product, delivery, and commercial capabilities globally. We are excited to partner with her as CEO in the next phase of Ennov’s growth and to continue to have Olivier’s stewardship as a board member.”

“We are delighted to welcome Oxana as CEO of Ennov,” said Alexis Saada, Head of Growth at Ardian. “Her extensive experience at the intersection of life sciences and enterprise software makes her ideally placed to lead the company through its next phase of growth. Alongside Bregal Sagemount, we look forward to supporting her and the wider Ennov team as they continue to strengthen the Company’s position as a trusted technology partner to the global life sciences industry.”

About Ennov:

Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 25 years of experience, Ennov’s cloud-based solutions cover Regulatory Affairs, Pharmacovigilance, Quality, Clinical, and Commercial. Dedicated to innovation and excellence, Ennov’s solutions are used by ~650 customers and over 500,000 users worldwide, helping them to bring their products to market faster while maintaining compliance with regulatory requirements. For more information, visit en.ennov.com or follow us on LinkedIn.

About Bregal Sagemount:

Bregal Sagemount is a leading growth-focused private capital firm with $11 billion of cumulative capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 90 companies in a variety of sectors, including software, data & information services, financial technology & services, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York and Palo Alto. For more information, visit www.sagemount.com or follow us on LinkedIn.

About Ardian:

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world. We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy. Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry. Ardian currently manages or advises $200bn for more than 1,920 clients worldwide across Private Equity, Real Assets, and Credit. Ardian. Mastering change for lasting value. For more information, visit ardian.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909904596/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vindral Named Recipient of 2026 Technology & Engineering Emmy® Award9.9.2026 18:38:00 CEST | Press release

Swedish real-time video company recognised alongside the world's leading media companies for frame-accurate remote production technology Vindral, the Swedish company building future-ready technology for real-time audio and video, has been named a recipient of a 2026 Technology & Engineering Emmy® Award by the National Academy of Television Arts & Sciences (NATAS). Vindral is recognised in the category Web-Based Frame-Accurate Remote Monitoring Systems for Distributed Broadcast Production. The co-recipients in the category are SipRadius, NBCUniversal, Grass Valley, CBS Sports, Disney, Game Creek and Amazon. The awards will be presented on October 14 at the Television Academy's Saban Media Center in North Hollywood, California, where Vindral will be represented by CEO Daniel Alinder and Ian Jefferson. The Technology & Engineering Emmy® Award is one of the U.S. television industry's most prestigious recognitions of technical achievement, previously awarded to companies including Apple, So

Elliptic Intelligence Used by the USSS to Take Action Against Xinbi, the $30 Billion Criminal Marketplace and Money Laundering Operation9.9.2026 18:36:00 CEST | Press release

Elliptic, the global leader in risk intelligence for on-chain finance, today confirmed that it provided the intelligence used by the United States Secret Service in action taken today against the Xinbi marketplace. The U.S. Secret Service froze wallets belonging to the marketplace and its merchants, containing $52.8 million in cryptoassets linked to Xinbi marketplace. Elliptic provided the data and intelligence that no other provider could. The data was extracted from Elliptic’s Data Fabric Solutions into the USSS' systems, giving investigators the one hundred thousand-foot view, connecting on-chain and off-chain data to paint a full picture of illicit activity rather than a snapshot in one screen of data. Data Fabric provides access to the same blockchain data and intelligence set behind Elliptic’s solutions, and that Elliptic’s own intelligence team used to expose both Huione and Xinbi before anyone else. Since beginning operations in 2022, Xinbi Guarantee and its merchants have proc

HOF Capital Completes €1 Billion Acquisition of Porsche’s Stakes in Bugatti Rimac and Rimac Group9.9.2026 18:00:00 CEST | Press release

HOF Capital today announced the completion of its acquisition of Porsche’s equity interests in Bugatti Rimac and Rimac Group through an HOF-led consortium. The transaction, first announced in April 2026, closed following the satisfaction of all conditions, including regulatory clearances. Porsche’s combined interests were valued at approximately €1 billion. HOF Capital originated and led the transaction, assembling a consortium of institutional investors from the United States and Europe. Following completion of the transaction, HOF holds a 23.5% stake and becomes the largest shareholder in Rimac Group, which holds the 55% controlling interest in Bugatti Rimac. HOF and its consortium also acquired Porsche’s direct 45% interest in Bugatti Rimac. As part of the investment, HOF Capital holds three supervisory board seats across Rimac Group and Bugatti Rimac. Hisham Elhaddad, Co-Founder and Managing Partner of HOF Capital, has joined the Supervisory Boards of both Bugatti Rimac and Rimac G

The Rock-It Company Expands Dynamic Dox to Provide ATA Carnet Services Across the US and Canada9.9.2026 17:00:00 CEST | Press release

Expansion provides access and expert ATA Carnet services for customers across new regions The Rock-It Company announced today the expansion of Dynamic Dox, the industry-leading provider of ATA Carnets, to now service partners and projects based in the United States, Canada and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909137375/en/ Following over a decade of expertise and leading service across the United Kingdom since 2014, Dynamic Dox will now provide new regions with dedicated document preparation for time-sensitive logistics projects, and urgent ATA Carnets for international shipments and critical business travel needs. The news of the expansion follows Dynamic Dox’s recent brand refresh, introducing an updated identity and connection to The Rock-It Company as Dynamic Dox By Rock-It. The expansion is led by Amanda Barlow, VP of Global ATA Carnets at The Rock-It Company, who has helped to drive the platfor

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release

- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye